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Mevalonate Cascade Inhibition by 
Simvastatin Induces the Intrinsic 
Apoptosis Pathway via Depletion of 
Isoprenoids in Tumor Cells
Javad Alizadeh1,2, Amir A. Zeki3, Nima Mirzaei1, Sandipan Tewary1, Adel Rezaei Moghadam1,2, 
Aleksandra Glogowska1, Pandian Nagakannan4, Eftekhar Eftekharpour4, Emilia Wiechec5, 
Joseph W. Gordon1,6, Fred. Y. Xu7, Jared T. Field8, Ken Y. Yoneda3, Nicholas J. Kenyon3, 
Mohammad Hashemi9, Grant M. Hatch7, Sabine Hombach-Klonisch1, Thomas Klonisch1 & 
Saeid Ghavami1,2,10
The mevalonate (MEV) cascade is responsible for cholesterol biosynthesis and the formation of the 
intermediate metabolites geranylgeranylpyrophosphate (GGPP) and farnesylpyrophosphate (FPP) 
used in the prenylation of proteins. Here we show that the MEV cascade inhibitor simvastatin induced 
significant cell death in a wide range of human tumor cell lines, including glioblastoma, astrocytoma, 
neuroblastoma, lung adenocarcinoma, and breast cancer. Simvastatin induced apoptotic cell death 
via the intrinsic apoptotic pathway. In all cancer cell types tested, simvastatin-induced cell death 
was not rescued by cholesterol, but was dependent on GGPP- and FPP-depletion. We confirmed that 
simvastatin caused the translocation of the small Rho GTPases RhoA, Cdc42, and Rac1/2/3 from 
cell membranes to the cytosol in U251 (glioblastoma), A549 (lung adenocarcinoma) and MDA-MB-
231(breast cancer). Simvastatin-induced Rho-GTP loading significantly increased in U251 cells which 
were reversed with MEV, FPP, GGPP. In contrast, simvastatin did not change Rho-GTP loading in A549 
and MDA-MB-231. Inhibition of geranylgeranyltransferase I by GGTi-298, but not farnesyltransferase 
by FTi-277, induced significant cell death in U251, A549, and MDA-MB-231. These results indicate that 
MEV cascade inhibition by simvastatin induced the intrinsic apoptosis pathway via inhibition of Rho 
family prenylation and depletion of GGPP, in a variety of different human cancer cell lines.
Tumor cells undergo significant metabolic reprogramming to serve their increased needs for energy and mac-
romolecules1,2. Cholesterol is essential for eukaryotic cells and critical for the propagation of tumor cells which 
utilize de novo cholesterol biosynthesis via fatty acid synthesis and the mevalonate (MEV) cascade3–5. The MEV 
pathway also generates non-sterol end products called isoprenoids, including isopentenyl pyrophosphate, 
farnesyl and geranylgeranyl isoprenoids, dolichol, ubiquinone, and isopentenyl adenine5,6. In eukaryotes, the 
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MEV pathway is the only metabolic pathway capable of generating the isoprenoids FPP and GGPP. In tumor cells, 
the MEV metabolism is dysregulated7,8 and glucose, glutamine, and acetate serve as substrates to fuel an anabolic 
MEV pathway5,9,10. 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) is the rate-limiting enzyme in the 
biosynthesis of MVA and cholesterol. Considered a new member of the family of metabolic oncogenes11, this key 
enzyme is frequently dysregulated in tumor cells12–15.
Statin drugs inhibit HMGCR and this can modulate several cellular signaling pathways relevant to tumor for-
mation, including angiogenesis, cellular proliferation, cell cycle regulation, gene expression, metastatic potential, 
and cell death5,16–18. Statins deplete cellular FPP, GGPP, and cholesterol by decreasing MEV levels5,19,20, cause cell 
cycle arrest by up-regulation of cyclin-dependent kinase inhibitors p2121 and p2722,23, induce apoptosis21,24–26 
and modulate proteasome activity27,28. While statin-mediated inhibition of small Rho GTPase prenylation (gera-
nylgeranylation and farnesylation) and cholesterol depletion are important contributing factors, the exact mech-
anisms of statin-induced apoptosis in tumor cells has not yet been fully elucidated.
The increased demand on the MEV pathway and its products during enhanced proliferation sensitizes tumor 
cells to inhibition of the MEV pathway by statins. Several recent epidemiological investigations confirmed a 
possible role of statins as anti-cancer agents29–31. In recent phase II clinical trials, lovastatin or pravastatin only 
showed limited inhibition of tumor growth21,32. However, their combination with different chemotherapeutic 
drugs produced more effective anti-tumor effects in several preclinical models32,33. According to www.clinical-
trials.gov there are approximately 153 clinical trials evaluating the use of statins as adjunctive or co-treatment for 
various types of cancers. The most common statins used in these studies is simvastatin (53) followed by atorvas-
tatin (37), rosuvastatin (21), pravastatin (18), lovastatin (11), and fluvastatin (3). This adds up to 143 studies, and 
the remaining 10 studies are looking at “statin use” and are inclusive of all statins.
This raises the important question of which cancers, which statins, and with which chemotherapeutic or radi-
ation combination will we produce the desired result of selective or preferential cancer cell apoptosis while reduc-
ing mortality. Therefore, elucidating these mechanisms remains of paramount importance if we hope to develop 
potentially more specific and effective targeted therapies based on the anti-cancer effects of statins. Our present 
study provides promising avenues to pursue this line of thinking.
In the present study, we investigated the ability of simvastatin to induce apoptosis in a broad range of human 
tumor cell lines of different origin. We hypothesized that statin-induced depletion of prenylation intermediates 
in the mevalonate cascade is responsible for apoptosis in cancer cells. Here we show that simvastatin-induced 
apoptosis was independent of cholesterol but required the prenylation intermediates GGPP and FPP.
Results
Simvastatin induces concentration- and time-dependent cell death in human brain, lung, 
and breast cancer cell lines. We initially tested the concentration (0–20 μ M) and time (0–96 h) effects 
of simvastatin on viability of glioblastoma (U87 (ATCC- HTB-14™ ), U251 (ATCC)), neuroblastoma (SH-SY5Y 
(ATCC-CRL-2266™ )), lung adenocarcinoma (A549 (ATCC- CCL-185™ ), H460 (ATCC- HTB-177™ ), H1650 
(ATCC-CRL-5883™ ), H1975 (ATCC-CRL-5908™ )), breast cancer (MCF-7 (ATCC-HTB-22™ ), MDA-MB-231 
(ATCC-HTB-26™ )), human astrocyte (Sciencell-1800), human HBE1(Gift from Dr. Amir Zeki lab, UC Davis), and 
human MCFD10A (Gift from Dr. Amir Zeki lab, UC Davis) (Fig. 1A–F) (Supplementary Fig. 1A–S). Simvastatin 
induces significant cell death in U87 (Fig. 1A,B) [(48 h, P < 0.01 for concentrations ≥ 5 μ M), (96 h, P < 0.001 
for concentrations ≥ 2.5 μ M)], U251 (Fig. 1C,D) [(48 h, 96 h P < 0.001 for concentrations ≥ 2.5 μ M)], SH-SY5Y 
(Fig. 1E,F) [(96 h, P < 0.001 for concentrations ≥ 2.5 μ M)], A549 (G, H) [(48 h, P < 0.01 for concentrations ≥ 
5 μ M), (96 h, P < 0.001 for concentrations ≥ 2.5 μ M)], H460 (I, J) [(48 h, P < 0.01 for concentrations ≥ 10 μ M), 
(96 h, P < 0.001 for concentrations ≥ 2.5 μ M)], H1650 (K, L) [(48 h, P < 0.01 for concentrations ≥ 5 μ M), (96 h, 
P < 0.001 for concentrations ≥ 1 μ M)], H1975 (M, N) [(48 h, P < 0.01 for concentrations ≥ 5 μ M), (96 h, P < 0.001 
for concentrations ≥ 1 μ M)], MCF-7 (O, P) [(48 h, P < 0.01 for concentrations ≥ 2.5 μ M), (96 h, P < 0.001 for 
concentrations ≥ 2.5 μ M)], MDA-MB-231 (Q, R) [(48 h, P < 0.001 for concentrations ≥ 1 μ M), (96 h, P < 0.0001 
for concentrations ≥ 1 μ M)]. The morphological changes of U87, A549, and MDA-MB213 cells observed when 
treated with simvastatin (10 μ M, 60 h) are shown in Fig. 1G. Our results also showed that simvastatin induced 
both time- and concentration-dependent significant cell death (P < 0.0001) in human astrocytes (Supplementa
ry Figure 1E and F), HBE1 (human bronchial epithelial cells) (Supplementary Figure 1M and N), and MCF10A 
(non-tumorigenic epithelial breast cell line) (Supplementary Figure 1Q and S). In summary, simvastatin induced 
a concentration- and time-dependent cell death in a broad range of human tumor and non-malignant cell lines.
Simvastatin induces the intrinsic apoptotic pathway in human cancer cells. We confirmed that 
simvastatin (10 μ M, 60 h) significantly induced apoptotic cell death in U87, U251, SH-SY5-Y, A549, H460, H1650, 
H1975, MCF-7, and MDA-MB-231 cell lines (Fig. 2A–D) (Supplementary Fig. 2A–F). As shown in Fig. 2D, an 
apoptotic cell population was identified as sub-G1 population in flow cytometry as had been described by us previ-
ously27. Simvastatin (10 μ M, 48 h) failed to activate caspase-8 but did activate caspase-9 and caspase-3/-7 in all cell 
lines tested at 36 h (Fig. 2E–G) (Supplementary Fig. 2G–L). These findings indicated that MEV cascade inhibition 
induced the intrinsic apoptotic pathways in all tumor cell lines tested. The involvement of the intrinsic apoptosis 
pathway was further confirmed by measuring mitochondrial membrane potential in simvastatin-treated (10 μ M, 
36 h) cells (U87, A549, MDA-MB231) (Fig. 2L–O). Simvastatin significantly reduced mitochondrial membrane 
potential in these tumor cells (U87, P < 0.01, A549, P < 0.05, and MDA-MB231, P < 0.001). We also showed that 
shorter treatment of simvastatin (10 mΜ , 18 h) did not change mitochondrial membrane potential in these cells 
(Fig. 2H–K) (P > 0.05).
Simvastatin-induced cell death in human cancer cells is not rescued by cholesterol but is 
dependent on depletion of FPP and GGPP. Statin-induced apoptosis is due to a loss of cell membrane 
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cholesterol and/or depletion of the polyisoprene cholesterol precursors, FPP and GGPP, which are essential lipid 
anchors for active small GTPase proteins in cells5,34,35. We used different approaches to identify the mechanism 
by which MEV cascade inhibition caused apoptosis. First, we performed treatment of tumor cells (U87, U251, 
A549, H460, H1650, H1975, MCF-7, MDA-MB-231) with simvastatin (10 μ M, 96 h) in the presence of MEV 
(2.5, 5 mM), cholesterol (25, 50 μ M), and next used FPP (7.5, 15 μ M), and GGPP (7.5, 15 μ M) pre-treatment and 
co-treatment in the cell models. MEV (Fig. 3A,C,E and Supplementary Fig. 3A,C,E,G,I,K), FPP (Fig. 4A,C,E, and 
Supplementary Fig. 4A,C,E,G,I,K), and GGPP (Fig. 4B,D,F, and Supplementary Fig. 4B,D,F,H,J,L) were each able 
to significantly inhibit (P < 0.001) simvastatin-induced cell death in all cell lines tested. However, cholesterol did 
not have any significant effect on simvastatin-induced cell death (Fig. 3B,D,F, and Supplementary Fig. 3B,D,F,H,J). 
Our results also showed that simvastatin significantly decreased total cholesterol (P < 0.01) and de novo choles-
terol biosynthesis (P < 0.001) in U251 cells (Fig. 3G,H). Simvastatin did not significantly change total cholesterol 
or de novo cholesterol biosynthesis (P > 0.05) in A549 (Fig. 3I,J) and MDA-MB231 cells (Fig. 3K,L).
Simvastatin blocks membrane translocation of Rho family small GTPases. We investigated the 
ability of simvastatin to affect the translocation of small Rho GTPases from the plasma membrane to the cytosol 
in U251 (Fig. 5A), A549 (Fig. 5C), and MDA-MB231 (Fig. 5E). Simvastatin decreased membrane localization of 
RhoA, Cdc42, and Rac/1/2/3 and their cytosolic cellular fraction suggesting simvastatin-mediated block in pre-
nylation of small GTPases and poor membrane translocation. We measured GTP-bound Rho protein and showed 
that simvastatin significantly (P < 0.05) increased GTP-bound Rho in U251 (Fig. 5B), whereas mevalonate, FPP, 
and GGPP co-treatment decreased GTP-bound Rho to untreated levels. Simvastatin did not significantly change 
Figure 1. Simvastatin induces cell death in glioblastoma, non-small lung cancer cell, and breast cancer cell 
lines. (A,B) U87 cells were treated with simvastatin (1, 2.5, 5, 10 or 20 μ M) and cell viability was assessed 48 and 
96 hrs thereafter by MTT assay. Control cells for each time point were treated with the solvent control (DMSO). 
Results are expressed as percentage of corresponding time point control and represent the means ± SD of 15 
replicates in three independent experiments (**P < 0.01; ***P < 0.001). (C,D) A549 cells were treated with 
simvastatin (1, 2.5, 5, 10 or 20 μ M) and cell viability was assessed 48 and 96 hrs thereafter by MTT assay. Control 
cells for each time point were treated with the solvent control (DMSO). Results are expressed as percentage of 
corresponding time point control and represent the means ± SD of 15 replicates in 3 independent experiments 
(**P < 0.01; ***P < 0.001). (E,F) MDA-MB-231 cells were treated with simvastatin (1, 2.5, 5, 10 or 20 μ M) and 
cell viability was assessed 48 and 96 hrs thereafter by MTT assay. Control cells for each time point were treated 
with the solvent control (DMSO). Results are expressed as percentage of corresponding time point control and 
represent the means ± SD of 15 replicates in three independent experiments (***P < 0.001). (G) U87, A549, 
and MDA-MB231 cells treated with 10 μ M simvastatin for 60 hrs were then photographed under phase contrast 
microscopy settings. Arrows indicate partially detached cells with condensed morphology.
www.nature.com/scientificreports/
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Figure 2. Simvastatin induces intrinsic apoptosis in glioblastoma, non-small lung cancer cell, and breast 
cancer cell lines. Percent sub-G1 (A) U87, (B) A549, (C) MDA-MB-231 abundance induced by simvastatin 
(10 μ M) or DMSO solvent control after 60 hrs. Results represent the means ± SD of 9 replicates in three 
independent experiments. *P < 0.05; and ***P < 0.001 compared to time-matched control. Representative 
figures of the flow cytometry histogram for U87, A549 and MDA-MB-231 are shown (D). Effects of simvastatin 
(10 μ M) treatment (36 hrs) on caspase-8, caspase-3/-7, and caspase-9 enzymatic activity, as detected by 
Caspase-Glo® luminometric assay in U87 (E), A549 (F), MDA-MB-231 (G). Caspase activity normalized to 
that measured for solvent-only treated cultures is represented on the Y-axis. The data represent mean ± SD 
of triplicate experiments performed on 3 independent experiments. U87, A549, and MDA-MB231 cells 
were treated with 10 μ M simvastatin for 18 and 36 hrs. Control cells were treated with media and vehicle 
control (DMSO). Cells were stained with TMRM, Hoechst, and imaged by standard fluorescence techniques. 
Simvastatin (10 μ M, 18 hrs) did not significantly change TMRM fluorescence intensity in U87, A549, and 
MDA-MB231 cells (H–K),while simvastatin (10 μ M, 36 hrs) significantly decreased TMRM florescence 
intensity in U87 (P < 0.01), A549 (P < 0.05), and MDA-MB231 (P < 0.001) (L–O) which indicates the decrease 
of mitochondrial membrane potential in simvastatin-treated cells. Data represent the average values from 
triplicates of three independent experiments.
www.nature.com/scientificreports/
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GTP-bound Rho protein in A549 (Fig. 5D) and MDA-MB-231 (Fig. 5F). Thus, simvastatin-induced small GTPase 
protein prenylation and intracellular localization may vary among different tumor cell lines.
Inhibitors of Geranygeranyltransferase and Farnesyltransferase Induce Differential Cell Death 
in Cancer Cells. Simvastatin-induced cell death in cancer cells was further investigated using farnesyl trans-
ferase inhibitor (FTi-277) and geranylgeranyl transferase I inhibitor (GGTi-298) in U87, A549, and MDA-MB231 
cells. FTi-277 (0–40 μ M, 36, 60 h) had no significant effect (P > 0.05) on cell death in all three cells in 36 h 
(Fig. 6A,C,E) and induced less than 15% death in U87 and A549 cells at 60 h (Fig. 6B,D). GGTi-298 (> 5 μ M) 
Figure 3. Simvastatin-induced cell death in glioblastoma, non-small lung cancer cell, and breast cancer 
cell lines is independent of cholesterol. 2.5, and 5 mM MEV or, 25, 50 μ M cholesterol, were added to the cells 
4 hrs prior to treatment with simvastatin (10 μ M, 96 hrs). Cell death was measured by MTT assay in U87 (A,B), 
A549 (C,D), and MDA-MB-231 (E,F). For each experiment control cells were treated with simvastatin solvent 
(DMSO) alone (control) or with both DMSO and the appropriate solvent (i.e. ethanol for “mevalonate control”). 
Results are expressed as mean ± SD of 9 replicate in 3 independent experiments (*P < 0.05, **P < 0.01, and 
***P < 0.001). U87, A549, and MDA-MB231 cells were treated with simvastatin (10 μ M) and after 36 hrs total 
and de novo cholesterol content in cells were measured. Both total and de novo cholesterol were significantly 
decreased in U251 cells (G,H) after simvastatin treatment. However, there was no significant change in the 
amount of total and de novo cholesterol for A549 (I,J) and MDA-MB231 cells (K,L). For each experiment 
control cells were treated with DMSO. Results are expressed as mean ± SD of 3 replicate 3 independent 
experiments (*P < 0.05, **P < 0.01, and ***P < 0.001).
www.nature.com/scientificreports/
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induced significant (P > 0.001) cell death in U87, A549, and MDA-MB231 cells (36 and 60 h, Fig. 6G–L), indi-
cating that gernylgernalytion was the leading mechanism in simvastatin-induced cell death in these cancer cells.
Discussion
In the present study, we found that MEV cascade inhibition by the HMGCR inhibitor simvastatin induced intrin-
sic apoptosis cell death and decreased mitochondrial membrane potential in a broad range of human tumor cell 
lines, including glioma (U87, U251), neuroblastoma (SH-SY5Y), lung (A549, H460, H1650, H1975), and breast 
cancer cells (MCF7, MDA-MB231). Inhibition of the MEV cascade prevented the membrane translocation of the 
small Rho GTPases RhoA, Cdc42 and Rac1/2/3 and this simvastatin effect was independent of cellular cholesterol 
but partially rescued by FPP and GGPP. Inhibition of FTase had no effect on cell death and FPP supplementation 
caused partial reversal of the simvastatin-mediated effects. FPP can also be converted into GGPP and the addition 
of FPP can restore farnesylation and geranylgeranylation. We also showed that, at least in U251 brain tumor cell 
line, the membrane localization of prenylated Rho GTPases was important for GTPase activity. Our findings are 
summarized in Fig. 7.
Simvastatin (10 μ M) is known to induce mitochondrial-dependent apoptotic cell death in brain tumor cell 
lines (U87 and U251) with subsequent activation of caspase-336. Lovastatin (5 μ M) can induce GGPP- and 
FPP-dependent apoptosis in U87 and U251 cells which is regulated by the expression of Bcl2 pro-apoptotic pro-
tein (Bim) in the absence of any changes in Blc2 anti-apoptotic protein expression37. Interestingly, lovastatin (10 μ 
M)-induced caspase-dependent apoptosis in SH-SY5Y cells was inhibited using caspase-3 (Z-DEVD-FMK) (50 μ 
M), and caspase-9 (Z-LEHD-FMK) (50 μ M) inhibitors37. Thus, statin mediates its cytotoxic effects via caspases of 
the intrinsic apoptotic pathway.
Simvastatin also induces pro-apoptotic Bcl2 family members Bcl2 and Bax in MCF-7 and MDA-MB231 cells 
in a time- and dose-dependent manner38,39. These effects were also caspase-dependent since simvastatin increased 
caspase-3 and -9 activity in MDA-MB231 cells39. Similarly, fluvastatin and atorvastatin, were also reported to 
induce dose- and time-dependent apoptosis in MCF-7 and MDA-MB-231 breast cancer cell lines40,41. Several 
mechanisms have been proposed for statin-induced cell death in breast cancer cells including an increase of 
Figure 4. Simvastatin-induced cell death in glioblastoma, non-small lung cancer cell, and breast cancer cell 
lines dependents on FPP and GGPP. 7.5, 15 μ M FPP, or 7.5, 15 μ M GGPP were added to the cells 4 hrs prior to 
treatment with simvastatin (10 μ M, 96 hrs) on cell death, measured by MTT assay in U87 (A,B), A549 (C,D), 
and MDA-MB-231 (E,F). For each experiment control cells were treated with simvastatin solvent (DMSO) 
alone (control) or with both DMSO and the appropriate solvent for each cholesterol precursor (i.e. DMSO 
for “FPP control” and “GGPP control”). Results are expressed as mean ± SD of 9 replicate in 3 independent 
experiments (*P < 0.05, **P < 0.01, and ***P < 0.001).
www.nature.com/scientificreports/
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Figure 5. Simvastatin promotes cytosolic localization of RhoA, CDC42, and Rac1/2/3. U87, A549, and 
MDA-MB231 were treated with simvastatin (10 μ M, 12, 24, 36 hrs) and the abundance of RhoA, cdc42, and 
Rac1/2/3 in membrane and cytosolic fractions obtained from U251 (A), A549 (C), and MDA-MB-231 (E). 
GAPDH and Pan-Cadherin abundance was also assessed to control for loading in cytosolic and membrane 
fractions, and to confirm lack of cytosolic contamination in membrane fractions. Data are typical of 3 
independent experiments using different primary cultures. Cropped representative of blots have been showed. 
G-LISA assay was done to evaluate the GTP-bound Rho protein in U251, A549, and MDA-MB231. Different 
conditions were tested for 36 hrs including starvation, Simva. (10 μ M), Mev (2.5 mM), FPP, and GGPP (15 μ 
M), Simva. + Mev, Simva. + FPP, and Simva. + GGPP. Simva. significantly increased GTP-bound Rho in U251 
cells (B) while Mev, FPP, and GGPP co-treatment decreased GTP-bound Rho compared to control. none of 
the treatments significantly change GTP-bound protein in A549 (D) and MDA-MB231 (F) cells. For each 
experiment a positive control provided in the kit was used and control cells were treated with the reagent in the 
kit. Results are expressed as mean ± SD of 2 replicates in an independent experiment (***P < 0.001).
www.nature.com/scientificreports/
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reactive oxygen species (ROS)42, the downregulation of survivin expression43, increased nitric oxide synthase 
activity (iNOS or NOS II) via geranylgeranylation44, and G1/S cell cycle arrest due to an increase in p21(Waf1/
Cip1)45.
Simvastatin was shown to induce caspase-dependent apoptosis in A549 cells which is regulated by the 
Bcl2 family proteins and ROS and can be reversed by treatment with N-acetylcysteine46,47. Other investi-
gators have reported that simvastatin can induce apoptotic pathways in A549 and H460 cells by blocking the 
Figure 6. FTi-277 and GGTi-298 induces differential cell death in cancer cells. U87, A549, and 
MDA-MB231 cells were treated with FTi-277 (0–40 μ M, 36, 60 hrs) (A–F) and GGTi-298 (0–40 μ M, 36, 60 hrs) 
(G–L) and the cytotoxic effects were measured using MTT assay. For each experiment control cells were treated 
with GGTi solvent (DMSO) and FTi-277 solvent (distilled water) alone (control). Results are expressed as 
mean ± SD of 15 replicate in 3 independent experiments (*P < 0.05, **P < 0.01, and ***P < 0.001).
Figure 7. Summary of the mechanism involved in statin-induced cell death in cancer cells. MEV cascade 
inhibitors induce the intrinsic apoptotic pathway which is regulated by gernaylgenralyation of small Rho 
GTPAse protein. 
www.nature.com/scientificreports/
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cell cycle and down-regulating cyclin D1 and cyclin dependent kinases (CDKs) expression48,49. In A549 cells, 
simvastatin-induced cell death was associated with decreased expression of survivin50, like in breast cancer cells.
Our previous investigations in human airway smooth muscle and fibroblasts and in human atrial fibroblasts 
showed that simvastatin induces the intrinsic apoptosis pathways in a small GTPase prenylation dependent way. 
This statin effect was not reversible with cholesterol co-treatment27,28,51. It has been also shown that GGTI-298, 
but not FTI-277, can mimic the cytotoxic effects of statins, indicating that statins induce cell death by inactivating 
Rho/Rac GTPase activities52. These results were also confirmed by translocation of RhoA, Rac1/2/3, and Cdc42 
to cytosol in simvastatin-treated cells. In eukaryotic cells, prenylation is carried out by three different prenyl 
transferases: farnesyl transferase (FT), geranylgeranyl transferase I (GGTI) and Rab geranylgeranyl transferase 
(Rab GGT or GGTII)53. FT is responsible for prenylation of proteins such as Ras and lamins. The GGTI catalyses 
the geranylgeranylation of proteins in the Rho and Rac family, whereas the Rab GGT is responsible for the ger-
anylgeranylation of the Rab protein family54. Simvastatin increases Rac GTP loading in THP-1 monocyte cells 
while decreasing prenylation of Rac in the presence of amyloid beta stimulation, and decreasing the induction of 
inflammation in these cells55. In addition, T-cell function is not affected by Rho GTP loading, whereas geranylger-
anylation of these small Rho GTPases is the determining step that affects their function56,57. Our results showed 
that statin-induced Rho protein GTP loading is dependent to specific cell type and Rho protein localization and 
geranylgeranylation is the determining step in regulation of their function (Figs 5, 6 and 7).
One of the signaling proteins involved in transmitting extracellular stimuli to intracellular components is the 
Ras (Rat sarcoma) superfamily of small GTPases5,58. In normal cellular and biological conditions these proteins 
play essential functions in the regulation of pathways critical to cytoskeletal reorganization, cell survival and 
proliferation, transformation, and vesicular trafficking59,60. One of the major subgroups in Ras superfamily of 
small GTPases is Rho (Ras homologous) family GTPases61. The members of small Rho GTPase (Rho, Rac, and 
Cdc42) are well known for their key functions in regulating actin cytoskeleton controlling actin stress fibers62–64. 
The function of small GTPases is very tightly regulated by different molecular switches, including prenylation 
and guanosine triphosphate (GTP) binding. When bound to GTP and prenylated, small GTPases not only trans-
locate to the membrane but also undergo a conformational change to engage effectors that promote downstream 
signaling pathways5,65.
In addition to their role in normal physiological and developmental processes, Rho GTPases can contribute 
to pathological processes including cancer cell migration, invasion, metastasis, and inflammation66,67. Activating 
mutations in Ras proteins (such as K-Ras, N-Ras, and H-Ras) are found in 15 to 30% of human tumors68. Several 
Rho proteins are upregulated in different human tumor types, including RhoA69,70, RhoC71, Rac169,70, Rac272, 
Rac373, and Cdc4269,70. Rac1 is overexpressed in breast70, lung74, oral squamous cell75, testicular76, and gastric 
carcinoma77, whereas RhoA is also overexpressed in breast70, colon78, lung64, gastric77, head and neck79, bladder80, 
and testicular carcinomas76,77,79–81. Cdc42 is overexpressed in breast69 and testicular cancers76. Therefore, inhibi-
tion of these over-expressed Rho small GTPases might improve current therapeutic approaches in the treatment 
these cancers.
There is increasing interest in repurposing statins for use in the treatment of human cancers. An epidemio-
logic study has shown that statin use in patients with cancer was associated with reduced cancer-related mortal-
ity82. Our results showed that the HMGCR inhibitor simvastatin induces intrinsic apoptotic cell death in different 
cancer cell models via a unique small Rho GTPase-dependent pathway which prevents small Rho GTPase pre-
nylation and inhibits subsequent translocation to the membrane, thus, effectively deactivating Rho GTPases. 
Interestingly, our current investigation suggests that cholesterol depletion is not involved in simvastatin-induced 
apoptosis in glioblastoma, neuroblastoma, non-small lung cancer cells, and breast cancer cell lines.
In our forthcoming studies, we are studying how the combination of simvastatin with different chemother-
apeutic agents may synergize to enhance cancer cell killing. We will explore mechanisms of cell fate that could 
mediate this beneficial statin effect, thereby supplementing and enhancing the therapeutic effects of cancer 
medications.
Materials and Methods
Reagents. Cell culture plastic ware, media, penicillin, streptomycin, and fetal bovine serum (FBS) were 
obtained from VWR (Toronto, ON, Canada). Secondary anti-rabbit and anti-mouse antibodies, propidium 
iodide (PI), simvastatin, mevalonate (Mev), farnesylpyrophosphate (FPP), geranylgeranylpyrophosphate 
(GGPP), GGTi-298, FTi-277, cholesterol, and 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bro-
mide) (MTT), were obtained from Sigma (Sigma-Aldrich, Oakville, CA). Rabbit anti-human/mouse Rac1/2/3, 
RhoA, and Cdc42 were purchased from Cell Signaling (Canada). Casapase-Glo® -3/7, Caspase-Glo® -8 and 
Caspase-Glo®-9 assay were purchased from Promega (Toronto, ON, Canada). Tetramethylrhodamine, Methyl 
Ester, Perchlorate (TMRM) was purchased from Biotium (Hayward, CA, USA). Thin layer chromatographic 
plates (silica gel G, 0.25-mm thickness) were from Fisher (Winnipeg, Manitoba, Canada). Ecolite scintillant was 
from ICN Biochemicals (Montreal, Quebec, Canada). Unlabeled cholesterol standard was from Sigma-Aldrich 
(Oakville, ON, Canada). [1-14C]Acetate was from American Radiolabeled Chemicals (St. Louis, MO, USA). All 
other biochemicals were American Chemical Society grade and were obtained from either Sigma-Aldrich or 
Fisher Scientific (Winnipeg, MB, Canada).
Cell Culture. For all experiments we used the following human cancer cell lines: (U87 (ATCC- HTB-14™ ), 
U251 (ATCC)), neuroblastoma (SH-SY5Y (ATCC-CRL-2266™ )), lung adenocarcinoma (A549 (ATCC- CCL-
185™ ), H460 (ATCC- HTB-177™ ), H1650 (ATCC-CRL-5883™ ), H1975 (ATCC-CRL-5908™ )), breast cancer 
(MCF-7 (ATCC-HTB-22™ ), MDA-MB-231 (ATCC-HTB-26™ )), human astrocyte (Sciencell-1800), human 
HBE1(Gift from Dr. Amir Zeki lab, UC Davis), and human MCFD10A (Gift from Dr. Amir Zeki lab, UC 
Davis). Cancer cells were cultured in DMEM (high glucose) supplemented with FBS (10%), penicillin (1%), and 
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streptomycin (1%). Human astrocytes were cultured in DMEM supplemented with FBS (10%), penicillin (1%), 
and streptomycin (1%). HBE1 cells were grown to 90% confluency on a 100 mm cell culture plate in serum-free 
medium containing Ham’s F12/DMEM (1:1), 15 mM NaHCO3, 15 mM Hepes (pH 7.4), with these factors: trans-
ferrin (5 μ g/mL), insulin (5 μ g/mL), cholera toxin (10 ng/mL), epidermal growth factor (10 ng/mL), dexametha-
sone (0.1 μ M), bovine hypothalamus extract (15 μ g/mL). Cells were then transferred to 6-well plates in submerged 
media conditions. MCF10A were grown in Lonza CC-3150 MEGM per ATCC’s recommendation without gen-
tamicin/amphotericinplus 100 ng/mL cholera toxin. Cells were then transferred to 6-well plates.
Cell Viability Assay. We measured the viability of different cancer cells under various treatment conditions, 
as described previously, using MTT assay28,83–85. Briefly, U87, U251, SH-SY5Y, A549, H460, H1650, H1975, 
MCF7, MDA-MB-231n normal astrocytes, HBE1, and MCF10A cells were treated with different concentrations 
of simvastatin for different time points (0–20 μ M, 0–96 h). Relative cell viability (percent of control) was calcu-
lated using the equation: (mean OD (570) of treated cells/mean OD (570) of control cells) × 100. For each time point, 
the treated cells were compared with control cells that had been treated with dimethyl sulfoxide (DMSO) vehicle 
only. In experiments investigating the role of MEV, GGPP, FPP, and cholesterol in mediating the cytotoxic effects 
of simvastatin on tumor cells, MEV (2.5 and 5 mM), GGPP (7.5 and 15 μ M), FPP (7.5 and 15 μ M), and cholesterol 
(25 and 50 μ M) were added to culture media 4 h before subsequent simvastatin co-treatment (10 μ M, 96 h). The 
cytotoxic effect of GGTi-298 and FTi-277 (0–40 μ M) in U87, A549, and MDA-MB-231, was evaluated using the 
same protocol as described for the simvastatin-induced cytotoxic assay.
Analysis of cellular morphology. To assess cell viability based on gross cellular appearance, U87, A549, 
and MDA-MB-231 cells were grown on 6 well plates, treated with simvastatin (10 μ M, 60 h) and assessed by phase 
contrast microscopy (Zeiss Axioverts 100) using a Olympus DP10 CCD digital camera to capture images27.
Measurement of Apoptosis by Flow Cytometry. The Nicoletti method was used to measure cellu-
lar apoptosis86,87. Briefly, cells cultured in 12 well plates were treated with simvastatin (10 μ M, 48 h). Cells were 
detached using EDTA buffer and harvested by centrifugation at 1500 g for 5 min at 4 °C. Cells were washed once 
in PBS before resuspending in a hypotonic PI lysis buffer (0.1% Triton X-100, 1% sodium citrate, 0.5 mg/ml 
RNase A, 40 μ g/ml propidium iodide). Cell nuclei were incubated at 37 °C for 30 min and analyzed by flow cytom-
etry. Apoptotic nuclei were located on the left side of the G1 peak and contained hypo-diploid DNA.
Luminometric Caspase Assay. For the proteolytic activity of caspase-8 (IETD-ase), -3/-7 (DEVD-ase), 
-9 (LEHDase), Caspase-Glo® -3/-7, -8, and -9 (Promega) were determined in luminometric assays accord-
ing to the manufacturer’s instructions and our previous report51,87. Briefly, cells were grown in 96-well plate 
(15,000 cells/well) and treated with simvastatin (10 μ M, 36 h). Fresh caspase reagents were prepared containing 
z-LETD-Luciferin, z-DEVD-Luciferin or z-LEHD-Luciferin and whole protein cell lysate extract buffer. Cells 
treated only with medium and reagent blank (negative controls) were included in each experiment. Plates were 
shaken gently at 300–500 rpm for 30 sec and then incubated for 90 min at room temperature. The solution was 
transferred to a white-well plate and then the luminescence was measured for each sample and compared to 
negative control values51,87.
TMRM Staining for Mitochondrial Membrane Potential Measurement. U87, A549, and 
MDA-MB231 cells were cultured in 6 well plates and were treated with simvastatin (10 μ M, 36 h) and then were 
stained with (Tetramethylrhodamine, Methyl Ester, Perchlorate TMRM (100 nM) and Hoechst (10 μ M) nuclear 
stain at 37 °C for 30 minutes. After washing, the cells they were imaged using florescence microscope and the 
fluorescence was quantified on ImageJ software in at least 50 individual cells in different views (NIH, Bethesda, 
MD, USA)88.
Membrane anchoring of Rho GTPases. To determine membrane anchoring of prenylated Rho and Rac 
GTPases, U251, A549, and MDA-MB-231 were cultured in DMEM with high glucose/10% FBS in the presence or 
absence of simvastatin (10 μ M, 36 h). Upon washing, cells were scraped in ice cold buffer (10 mM Tris–HCl, pH 
7.5, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM dithiothreitol, and protease inhibitor cocktail), sonicated on ice three 
times for 5 sec and cell homogenate was separated into cytoplasmic and membrane fractions by ultracentrifuga-
tion (100,000 × g for 35 min)89. Membrane fractions were solubilized in dissociation buffer (50 mM Tris–HCl, 
pH 7.5, 0.15 M NaCl, 1 mM dithiothreitol, 1% SDS, 1 mM EDTA, 1 mM EGTA, protease inhibitor cocktail), and 
subsequently size fractioned by SDS–PAGE (15%) for immunoblot analysis using primary antibodies to Rac1/2/3, 
Cdc42, and RhoA (all Cell Signaling)27.
Measurement of Rho GTPase activity. Rho-GTP bound was measured in snap-frozen cell lysates har-
vested from cells cultured in medium without FBS and treated with simvastatin (10 μ M), mevalonate (2.5 mM), 
FPP, and GGPP (15 μ M), Simva. + mevalonate, simvastatin + FPP, and simvastatin + GGPP for 36 h. We used 
a luminometric-based G-LISA Rho –GTP bound assay (Cytoskeleton, Inc, Denver, Colo) for U251, A549, and 
MDA-MB231 cells Briefly, cell lysates were subjected to Rho binding domain in a Rho-GTP affinity 96-well plate 
(Cytoskeleton, Inc, Denver, Colo). Rho-GTP was detected with specific primary antibody, followed by horserad-
ish peroxidase-conjugated secondary antibody detection and development with a chemiluminescent reagent. A 
constitutively active Rho-GTP provided in the kit was used as positive control in all experiments90.
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Cholesterol mass measurement. U87, A549, and MDA-MB231 cells were treated with simvastatin (10 μ 
M, 36 h) and subsequently cholesterol content of cells was determined by colorimetric reaction using the Amplex 
Red Cholesterol assay kit (Invitrogen) as per the manufacturer’s instructions. Lipids were extracted and choles-
terol isolated on thin layer chromatography plates prior to analysis as described27,91–93. All isolates were measured 
immediately after drying down under N2.
Cholesterol labeling experiment. Cells were incubated with 0.1 μ M [1-14C]acetate (10 μ Ci/dish) for 24 h. 
Lipids were extracted and cholesterol isolated on thin layer chromatography plates as above. Spots correspond-
ing to cholesterol standards were removed, and radioactivity incorporated into cholesterol determined by liquid 
scintillation counting as described92.
Immunoblotting. Western blotting was used to detect Cdc42, Rac1/2/3 and RhoA in membrane and 
cytosolic fractions as described previously51,94. Pan-cadherin and GAPDH were used to confirm membrane 
and cytosolic fraction purity, respectively. Briefly, cells protein extracts were prepared in lysis buffer (20 mM 
Tris-HCl (pH 7.5), 0.5 mM PMSF, 0.5% Nonidet P-40, 100 μ M β -glycerol 3-phosphate and 0.5% protease inhib-
itor cocktail). Supernatant protein content was measured by Lowry protein assay after centrifugation at 13,000 g 
for 10 min. Proteins were separated by SDS-PAGE and transferred to nylon membranes under reducing condi-
tions. Membranes were blocked with non-fat dried milk and Tween 20 followed by overnight incubation with 
the primary antibodies at 4 °C, followed by incubation with HRP-conjugated secondary antibody for 1 h at room 
temperature. Blots were developed by enhanced chemiluminescence (ECL) detection (Amersham-Pharmacia 
Biotech).
Statistical Analysis. The results were expressed as means ± SEM and statistical differences were evaluated 
by one-way or two-way ANOVA followed by Tukey’s or Bonferroni’s post hoc testing, using Graph Pad Prism 7.0. 
A p-value < 0.05 was considered statistically significant. For all experiments data were collected in five replicates 
and in three separate experiments.
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